
Fan Xia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4254594/publications.pdf Version: 2024-02-01



EAN XIA

#	Article	IF	CITATIONS
1	Modulation of the Gut Microbiota in Rats by Hugan Qingzhi Tablets during the Treatment of High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-14.	4.0	99
2	The probiotic effects of AB23A on high-fat-diet-induced non-alcoholic fatty liver disease in mice may be associated with suppressing the serum levels of lipopolysaccharides and branched-chain amino acids. Archives of Biochemistry and Biophysics, 2021, 714, 109080.	3.0	30
3	lsobaric tags for relative and absolute quantitation (iTRAQ)-based proteomics for the investigation of the effect of Hugan Qingzhi on non-alcoholic fatty liver disease in rats. Journal of Ethnopharmacology, 2018, 212, 208-215.	4.1	25
4	Gut microbiota as a target for prevention and treatment of type 2 diabetes: Mechanisms and dietary natural products. World Journal of Diabetes, 2021, 12, 1146-1163.	3.5	23
5	The dietary flavonoid isoliquiritigenin induced apoptosis and suppressed metastasis in melanoma cells: An in vitro and in vivo study. Life Sciences, 2021, 264, 118598.	4.3	15
6	Ficus hirta Vahl. Ameliorates Nonalcoholic Fatty Liver Disease through Regulating Lipid Metabolism and Gut Microbiota. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-31.	4.0	9
7	Hugan Qingzhi medication ameliorates free fatty acid-induced L02 hepatocyte endoplasmic reticulum stress by regulating the activation of PKC-δ. BMC Complementary Medicine and Therapies, 2020, 20, 377.	2.7	5
8	Data for iTRAQ-based quantification of the effect of HuganQingzhi on non-alcoholic fatty liver disease in rats. Data in Brief, 2017, 15, 612-614.	1.0	0